This invention relates to D2 dopaminergic compounds of the formula wherein: R1 is hydrogen, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, straight-chain or branched alkyl group having up to 6 carbons or benzyl optionally substituted by one to three substituents selected from halogen, amino, nitro, hydroxy, and C1-C6 alkoxy; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen, straight-chain or branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl, -(CH2)mAr where Ar is phenyl, naphthalenyl, thienyl, furanyl, or pyridinyl, each optionally substituted by one to two substituents selected from halogen, C1-C6 alkoxy, trifluoromethyl and C1-C6 alkyl, and m is 1-3 or NR2R3 is 1,2,3,4-tetrahydroquinolin-1-yl or 1,2,3,4-tetrahydroisoquinolin-2-yl; Y is hydrogen, halogen, lower alkyl, amino, or lower alkoxy; n is 1-5: or a pharmaceutically acceptable salt thereof. These D2 dopaminergic compounds are useful in the treatment of schizophrenia, Parkinson's disease, Tourette's syndrome, and drug or alcohol addiction.
4-aminoalkoxy-1H-benzoimidazoles